Grace Therapeutics, Inc reports results for the quarter ended June 30 - Earnings Summary

Grace Therapeutics

12/08/2025 13:43

Grace Therapeutics, Inc GRCE.OQ reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -27 cents.  The mean expectation of two analysts for the quarter was for a loss of 22 cents per share.

Reported revenue was zero​; analysts expected zero.

Grace Therapeutics, Inc's reported EPS for the quarter was a loss of 21 cents​.

The company reported a quarterly loss of $3.36 million.

Grace Therapeutics, Inc shares had risen by 4.4% this quarter and lost 17.1% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Grace Therapeutics, Inc is $12.00, about 74.2% above its last closing price of $3.10

This summary was machine generated from LSEG data August 12 at 12:43 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.22
-0.21
Beat
Mar. 31 2025
-0.31
0.10
Beat
Dec. 31 2024
-0.43
-0.26
Beat
Sep. 30 2024
-0.45
-0.33
Beat